GLPG Live signals | Maximize Profits with Getagraph.com

BUY 106060 min ago

@ $39.44

Issued: 12 Feb 2024 @ 09:30

Return: -27.41%

Previous signal: Feb 9 - 09:30

Previous signal: Sell

Return: 0.23 %

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need...

Stats
Today's Volume	167 619
Average Volume	125 000
Market Cap	1.89B
EPS	$0 ( 2024-03-08 )
Next earnings date	( $-0.120 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-477.17
ATR14	$0.0240 (0.08%)

Volume Correlation

Long: -0.03 (neutral)

Short: 0.82 (strong)

Signal:(62.294) Same movement expected

Galapagos NV Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Galapagos NV Correlation - Currency/Commodity

-0.05
( neutral )

0.02
( neutral )

0.00
( neutral )

0.06
( neutral )

-0.31
( neutral )

-0.29
( neutral )

Galapagos NV Financials

Annual	2023
Revenue:	$239.72M
Gross Profit:	$239.70M (99.99 %)
EPS:	$3.21

Q4	2023
Revenue:	$-209.12M
Gross Profit:	$-293.55M (140.37 %)
EPS:	$-0.880

Q3	2023
Revenue:	$120.03M
Gross Profit:	$114.33M (95.25 %)
EPS:	$0.390

Q2	2023
Revenue:	$149.95M
Gross Profit:	$145.69M (97.15 %)
EPS:	$0.0774

Financial Reports:

No articles found.

Galapagos NV

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.